Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Watchlisten für Ihre Werte
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON

SANTHERA PHARMACEUTICALS HOLDING AG

(SANN)
  Bericht
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-NewsMarketScreener Analysen
Nachrichten in anderen Sprachen über SANTHERA PHARMACEUTICALS HOLDING AG
04.01.SANTHERA : licence exclusive conclue avec Sperogenix pour le Vamorolone
04.01.Santhera Enters into Exclusive License Agreement with Sperogenix for Vamorolone in Rare..
04.01.Santhera Pharmaceuticals Enters into Exclusive License Agreement with Sperogenix for Va..
2021SANTHERA : les actionnaires approuvent l'augmentation de capital
2021Santhera's Shareholders Approve all Board Proposals at Today's Extraordinary General Me..
2021Santhera's Shareholders Approve all Board Proposals at Today's Extraordinary General Me..
2021Santhera Pharmaceuticals Holding AG announced that it expects to receive CHF 20 million..
2021Santhera optimiste pour son médicament vamorolone
2021Santhera to Host Investor Conference Call, Looking Ahead to 2022
2021Santhera to File Rolling New Drug Application for Duchenne Treatment to US FDA in Early..
2021Santhera to Host Investor Conference Call — Looking Ahead to 2022
2021Santhera veut demander 20 millions de francs supplémentaires en décembre
2021Santhera's Board Calls Extraordinary General Meeting To Vote On Future Fundraisings
2021Santhera Provides Corporate Update and Calls Extraordinary General Meeting to Seek Appr..
2021Santhera Pharmaceuticals Holding AG announced that it has received CHF 15 million in fu..
2021Santhera revendique le succès d'un programme contre la maladie de Duchenne
2021Santhera's Mid-Stage Trial For Duchenne Muscular Dystrophy Drug Shows Sustained Efficac..
2021Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completi..
2021Santhera JV to Seek US FDA's New Drug Approval For Duchenne Muscular Dystrophy Treatmen..
2021Santhera and ReveraGen Announce Successful FDA Pre-NDA Meeting for Vamorolone in Duchen..
2021Santhera Pharmaceuticals and ReveraGen Biopharma Announces Successful FDA Pre-NDA Meeti..
2021Santhera intègre Stephanie Brown à la direction générale
2021Santhera Appoints Stephanie Brown as President North America and Member of the Executiv..
2021Santhera Pharmaceuticals Holding AG Appoints Stephanie Brown as President North America..
2021SANTHERA PHARMACEUTICALS : H1 Loss Narrows As Operating Expenses Decline
2021Santhera a définitivement fait une perte semestrielle de 20,5 millions de francs
2021Santhera Announces First Half-Year 2021 Financial Results and Updates on Corporate Prog..
2021SANTHERA PHARMACEUTICALS : 2021 Santhera Interim Report
2021SANTHERA : SIX accorde un délai au 15 octobre pour les résultats semestriels
2021Santhera will Publish its Interim Report for the First Half of 2021 on October 15, 2021
2021Santhera a émis 8,1 millions d'actions et reçoit une subvention aux Etats-Unis
2021SANTHERA PHARMACEUTICALS : ReveraGen Get US FDA Orphan Grant to Study Vamorolone in Becker..
2021SANTHERA PHARMACEUTICALS : Issues Remaining Shares in $22 Million Private Placement
2021ReveraGen and Santhera Announce FDA Orphan Grant Funding for Clinical Trial with Vamoro..
2021Santhera Completes Subsequent Capital Increase for Financing Arrangements
2021Santhera finalise son augmentation de capital
2021SANTHERA PHARMACEUTICALS : Vamorolone Improves Outcomes For Duchenne Muscular Dystrophy Pa..
2021SANTHERA PHARMACEUTICALS : Issues 10 Million Shares in Private Placement
2021Santhera and ReveraGen to Present Phase 2a/2b Efficacy and New Safety Data with Vamorol..
2021Santhera Completes Capital Increase for Financing Arrangements
2021Encore dans le rouge au 1er semestre, Santhera a levé 45 millions de francs
2021SANTHERA PHARMACEUTICALS : Raises $48 Million Funds
2021SANTHERA PHARMACEUTICALS : H1 Loss Shrinks On Financial Gain From Bond Conversions
2021Santhera Secures CHF 45 Million in Funding and Announces Preliminary First Half-Year 20..
2021Santhera Pharmaceuticals Holding AG announced that it expects to receive CHF 15 million..
2021SANTHERA PHARMACEUTICALS' : Vamorolone Shows Positive Results In Duchenne Muscular Dystrop..
2021Santhera and ReveraGen to Present Findings from Pivotal VISION-DMD Study with Vamorolon..
2021Santhera Pharmaceuticals and ReveraGen BioPharma, Inc. to Present Findings from Pivotal..
2021Santhera and ReveraGen to Present Findings from Pivotal VISION-DMD Study with Vamorolon..
2021SANTHERA PHARMACEUTICALS : Shareholders Approve all Board Proposals at Today's Annual Gene..
2021Santhera revendique le succès d'une étude de suivi sur le Raxone
2021SANTHERA PHARMACEUTICALS' : Trial For Raxone Meets Primary Endpoint In Vision Loss Disease
2021Santhera Announces Phase 4 LEROS Trial with Raxone(R) Met Primary Endpoint in Patients ..
2021Santhera Pharmaceuticals Holding AG Announces Phase 4 LEROS Trial with Raxone® Met Prim..
2021Santhera Announces Phase 4 LEROS Trial with Raxone® Met Primary Endpoint in Patients wi..
2021SANTHERA : toutes les propositions acceptées à l'assemblée générale
2021Santhera's Shareholders Approve all Board Proposals at Today's Annual General Meeting
2021SANTHERA PHARMACEUTICALS : Meets Primary Endpoint For Vamorolone In Duchenne Muscular Dyst..
2021EN DIRECT DES MARCHES  : Sanofi, Axa, Atos, AB Science, Vallourec, Nacon, Volkswagen, Clou..
2021Santhera revendique le succès d'un programme contre la maladie de Duchenne
2021SANTHERA PHARMACEUTICALS : and ReveraGen Announce Positive and Statistically Highly Signif..
2021Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline R..
2021SANTHERA PHARMACEUTICALS : Vice Chair to Step Down
2021Santhera requiert de nouvelles augmentations de capital à ses actionnaires
2021Santhera Publishes Agenda for its Annual General Meeting
2021Santhera émet de nouvelles actions pour se refinancer
2021Santhera Completes Capital Increase for Financing Arrangements
2021SANTHERA : premier jour de négoce pour le nouvel emprunt convertible
2021SANTHERA PHARMACEUTICALS : gibt den ersten Handelstag der neuen Wandelanleihe an der SIX S..
2021Santhera Announces First Trading Day of New Convertible Bonds on SIX Swiss Exchange
2021SANTHERA PHARMACEUTICALS : gibt den Vollzug des Umtauschangebots und die Ausgabe einer neu..
2021Santhera Announces Settlement of Exchange Offer and Issuance of New Senior Unsecured Co..
2021SANTHERA PHARMACEUTICALS : Announces Settlement of Convertible Bond Exchange Offer on
2021SANTHERA : réalisation de l'offre pour le convertible au 4 mai 2021
2021SANTHERA PHARMACEUTICALS : gibt den Vollzug des Umtauschangebots für die Wandelanleihe per..
1  2  3  4  5  6  7  8  9Weiter